Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
0.774
-0.001 (-0.08%)
Nov 21, 2024, 1:56 PM EST - Market open
Karyopharm Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for KPTI stock have an average target of 5.00, with a low estimate of 3.00 and a high estimate of 7.00. The average target predicts an increase of 545.66% from the current stock price of 0.77.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KPTI stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +545.66% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +803.93% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +803.93% | Nov 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +803.93% | Aug 7, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $3 | Buy | Reiterates | $3 | +287.40% | Aug 7, 2024 |
Financial Forecast
Revenue This Year
155.78M
from 146.03M
Increased by 6.67%
Revenue Next Year
169.15M
from 155.78M
Increased by 8.58%
EPS This Year
-0.68
from -1.25
EPS Next Year
-0.73
from -0.68
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 162.8M | 204.8M | 251.2M | ||
| Avg | 155.8M | 169.2M | 206.1M | ||
| Low | 147.0M | 136.3M | 171.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 11.5% | 31.5% | 48.5% | ||
| Avg | 6.7% | 8.6% | 21.9% | ||
| Low | 0.7% | -12.5% | 1.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.64 | -0.44 | -0.32 | ||
| Avg | -0.68 | -0.73 | -0.46 | ||
| Low | -0.77 | -1.04 | -0.63 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.